1. Pink Sheet

BMS’ Cell Therapy For Lymphoma On Track For EU-Wide Approval

Breyanzi’s EU Approval Will Introduce A Third CAR-T Therapy To The LBCL Market

 
• By Vibha Sharma

Several new drugs are now on track for an EU marketing authorization after getting the EMA’s thumbs up this week. 

gene therapy
Each dose of Breyanzi is created by collecting and genetically modifying a patient’s own immune cells to treat their cancer • Source: Alamy (Alamy Stock Photo)

Bristol Myers Squibb’s CAR-T therapy Breyanzi (lisocabtagene maraleucel) for treating large B-cell lymphoma is among several new drugs to be recommended for pan-EU approval this week.

If approved, Breyanzi will become the third CAR-T therapy on the European LBCL market

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Cell & Gene Therapies

More from Advanced Technologies